Compare LNTH & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | DLB |
|---|---|---|
| Founded | 1956 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.8B |
| IPO Year | 2014 | 2004 |
| Metric | LNTH | DLB |
|---|---|---|
| Price | $100.69 | $53.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $87.00 | ★ $90.75 |
| AVG Volume (30 Days) | ★ 1.0M | 812.6K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.80 | 1.54 |
| Revenue | ★ $343,374,000.00 | N/A |
| Revenue This Year | N/A | $6.22 |
| Revenue Next Year | $14.19 | $3.84 |
| P/E Ratio | $57.12 | ★ $35.09 |
| Revenue Growth | ★ 3.62 | N/A |
| 52 Week Low | $47.27 | $52.45 |
| 52 Week High | $103.75 | $76.91 |
| Indicator | LNTH | DLB |
|---|---|---|
| Relative Strength Index (RSI) | 65.83 | 35.22 |
| Support Level | $91.65 | $52.45 |
| Resistance Level | $102.66 | $68.75 |
| Average True Range (ATR) | 3.38 | 1.59 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 77.09 | 18.91 |
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.